Newron publishes agenda for Shareholder's meeting

Newron publishes agenda for Shareholder's meeting

Milan, Italy - 9 November 2012 - Newron Pharmaceuticals S.p.A. ("Newron", SIX:
NWRN), a research and development company focused on Central Nervous System
(CNS) and pain therapies, announces the decision by its Board of Directors to
call for a Shareholder's meeting, which will take place at Haus Zum Rueden,
Zurich, on 5 December 2012, 11.30am CET. Items on the agenda will include:

1. Increase in the share capital, severable, up to nominal Euro 475.000,00,
plus a premium, by issuance for payment and with exclusion of the option right
pursuant to article 2441, paragraph 4, of the Italian civil code, of up to n.
2.375.000 ordinary shares of Newron Pharmaceuticals S.p.A. having a par value
of Euro 0.20 each, to be subscribed via contribution in kind of shares of
NeuroNova AB.

2. Revocation - in case of execution, even partial, by February 28, 2013, of
the share capital increase to be subscribed via contribution in kind of shares
of NeuroNova AB as described in paragraph 1 of this agenda - of the increase
in the Company's share capital resolved by the shareholders' meeting on 28
June 2012, severable, with option right for the Company's current shareholders
pursuant to Article 2441 of the Italian Civil Code, for payment, up to a
maximum par value of Euro 400,000.00, of which a quarter of the newly issued
ordinary shares to be offered to employees of the Company or its subsidiaries
with exclusion of the option right pursuant to Article 2441, paragraph 8, of
the Italian Civil Code.

3. Subject to the execution, even partial, within February 28, 2013, of the
share capital increase to be subscribed via contribution in kind of shares of
NeuroNova AB as described in paragraph 1 of this agenda, amendment of the
number of the members of the Board of Directors from 6 up to 7, appointment of
a director as proposed by NeuroNova AB current shareholders and determination
of his relevant remuneration, in line with remuneration of current non
executive directors.

Rolf Stahel, Chairman of Newron, said: "I am delighted that we are able to
submit the new agreement to acquire NeuroNova to our shareholders, which we
believe has brought shareholders' support. We are encouraging our shareholders
to register and vote at the upcoming meeting in Zurich."

Stefan Weber, CEO of Newron, continued: "The acquisition strengthens Newron's
development pipeline with two highly innovative compounds and brings
additional funds in order to advance them to the next value creation point. At
the same time, we will strengthen our shareholder structure, now with lower
dilution to our existing shareholders."

The full invitation, including detailed information for shareholders, will be
available on the Company's website within short, see

About Newron Pharmaceuticals

Newron (SIX: NWRN) is a biopharmaceutical company focused on novel therapies
for diseases of the Central Nervous System (CNS) and pain. The Company is
headquartered in Bresso near Milan, Italy. Phase III trials of safinamide for
the treatment of Parkinson's disease (PD) have recently been completed. Based
on the phase III results of safinamide, Newron is working to expedite the
global filing of the compound, together with its partners. Zambon Group has
the rights to commercialise safinamide globally, excluding Japan and other key
Asian territories, and Meiji Seika has the rights to develop and commercialise
safinamide in Japan and other key Asian territories. Newron's additional
projects are primarily addressed towards highly promising rare diseases and
are at various stages of preclinical and clinical development, including
sarizotane for Rett's syndrome, ralfinamide for specific pain indications, and
NW-3509 as potential first add-on therapy for the treatment of schizophrenia.

For more information, contact:

Media                       Investors and analysts

Stefan Weber - CEO

Phone: +39 02 6103 46 26


UK/Global media
                            Stefan Weber - CEO
Julia Phillips
                            Phone: +39 02 6103 46 30
FTI Consulting
Phone: +44 (0) 20 7269 7187


Martin Meier-Pfister

IRF Communications

Phone: +41 43 244 81 40

Important Notices

This document contains forward-looking statements, including (without
limitation) about (1) Newron's ability to develop and expand its business,
successfully complete development of its current product candidates and
current and future collaborations for the development and commercialisation of
its product candidates and reduce costs (including staff costs), (2) the
market for drugs to treat CNS diseases and pain conditions, (3) Newron's
anticipated future revenues, capital expenditures and financial resources, and
(4) assumptions underlying any such statements. In some cases these statements
and assumptions can be identified by the fact that they use words such as
"will", "anticipate", "estimate", "expect", "project", "intend", "plan",
"believe", "target", and other words and terms of similar meaning. All
statements, other than historical facts, contained herein regarding Newron's
strategy, goals, plans, future financial position, projected revenues and
costs and prospects are forward-looking statements.

By their very nature, such statements and assumptions involve inherent risks
and uncertainties, both general and specific, and risks exist that
predictions, forecasts, projections and other outcomes described, assumed or
implied therein will not be achieved. Future events and actual results could
differ materially from those set out in, contemplated by or underlying the
forward-looking statements due to a number of important factors. These factors
include (without limitation) (1) uncertainties in the discovery, development
or marketing of products, including without limitation negative results of
clinical trials or research projects or unexpected side effects, (2) delay or
inability in obtaining regulatory approvals or bringing products to market,
(3) future market acceptance of products, (4) loss of or inability to obtain
adequate protection for intellectual property rights, (5) inability to raise
additional funds, (6) success of existing and entry into future collaborations
and licensing agreements, (7) litigation, (8) loss of key executive or other
employees, (9) adverse publicity and news coverage, and (10) competition,
regulatory, legislative and judicial developments or changes in market and/or
overall economic conditions.

Newron may not actually achieve the plans, intentions or expectations
disclosed in forward-looking statements and assumptions underlying any such
statements may prove wrong. Investors should therefore not place undue
reliance on them. There can be no assurance that actual results of Newron's
research programmes, development activities, commercialisation plans,
collaborations and operations will not differ materially from the expectations
set out in such forward-looking statements or underlying assumptions.

Newron does not undertake any obligation to publicly up-date or revise forward
looking statements except as may be required by applicable regulations of the
SIX Swiss Exchange where the shares of Newron are listed.

This document does not contain or constitute an offer or invitation to
purchase or subscribe for any securities of Newron and no part of it shall
form the basis of or be relied upon in connection with any contract or
commitment whatsoever.

Press release (PDF)

Provider                  Channel         Contact
Tensid Ltd., Switzerland      Provider/Channel related enquiries   
                                          +41 41 763 00 50
Press spacebar to pause and continue. Press esc to stop.